Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA®) in Adults With Moderate to Severe Plaque Psoriasis

NCT01970488 · clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
350
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Amgen